Achyut Healthcare Ltd
₹
- close price
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Upcoming result date: today
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Export sales as % of revenue from operations % ・Standalone data |
|
||||
| Number of permanent employees on rolls employees ・Standalone data |
|||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Submission Of Statement Of Deviation Or Variation For Proceeds Of Public Issue Pursuant To Regulation 32 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015 For The Quarter And Half Year Ended On 30Th September, 2026
- Filed Regulation 32 statement for quarter ended 30 Sep 2026; no deviation in public issue proceeds.
- Unaudited Result September, 2026
-
Board Meeting Outcome for Outcome Of Board Meeting
- Board approved Q2/H1 FY27 results on 26 Oct 2026; revenue ₹478.82 lakh, net profit ₹19.26 lakh.
-
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Monday, October 26, 2026
- Board meeting on 26 Oct 2026 to approve Q2 and half-year FY2026 results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Submission of RTA Certificate/Confirmation/Deceleration pursuant to Regulation 74(5) of SEBI (Depositories And Participants) Regulation 2018 for the quarter ended 30.09.2026 of F.Y. 2026-27.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
Current vs legacy business:[1]
The operating business remains trading/dealing in APIs and pharmaceutical products; In FY26 accounts classify purchases as “traded goods”. The company entered pharma trading in 2015 after its earlier securities-company history.[2]